Mental Retardation 
Welcome,         Profile    Billing    Logout  

163 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Mental Retardation
2019-003369-16: An irregular trial in which the identity of those receiving the intervention in twin groups is concealed from both the administrators and subject until the test is completed. The trial is to check the safety and efficacy of GWP42003-P versus Placebo as a joining therapy in Participants with Schizophrenia Experiencing Inadequate Response to Ongoing Antipsychotic Treatment. Un ensayo irregular en el que la identidad de quienes reciben la intervención en grupos gemelos se oculta tanto a los administradores como al sujeto hasta que se completa la prueba.El estudio es para investigar la seguridad y la eficacia de GWP42003-P frente a placebo como tratamiento complementario en participantes con esquizofrenia que experimenten respuesta inadecuada al tratamiento con antipsicóticos en curso.

Not yet recruiting
2
366
Europe
Cannabidiol (CBD), GWP42003-P, Oral solution, CBD-Oral Solution, is known as Epidyolex, and is the approved name in the EU
GW Research Ltd., GW Research Ltd
Schizophrenia is neurodevelopmental syndrome, results from gradual alterations in brain connectivity. Can persist for years before psychosis emerges. Individuals have a 2 to 3 fold increased risk of death from a range of comorbid somatic conditions and suicide, the former attributable to unhealthy lifestyle, predisposition, and antipsychotic medication. Individuals typically smoke, can be overweight or obese, suffer from hypertension, dyslipidemias, metabolic syndrome, and diabetes. Esquizofrenia es un síndrome del neurodesarrollo resultado de alteraciones graduales en la conectividad cerebral.Puede persistir durante años antes de que surja la psicosis.El riesgo de muerte es de 2 a 3 veces mayor debido a una variedad de afecciones somáticas comórbidas y suicidio,el primero atribuible a un estilo de vida poco saludable,predisposición y medicamentos antipsicóticos. Las personas suelen fumar,tener sobrepeso u obesidad, hipertensión,dislipidemias,síndrome metabólico ydiabetes, schizophrenia is a severe long-term mental health condition. It causes a range of different psychological symptoms. La esquizofrenia es una afección grave de salud mental a largo plazo. Causa una variedad de síntomas psicológicos diferentes, Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
2021-004790-31: A Clinical Study to Investigate the Efficacy, Safety and Tolerability of JNJ-55308942 in Bipolar Depression Estudio para analizar la eficacia, la seguridad y la tolerabilidad de JNJ-55308942 en el tratamiento de la depresión bipolar

Ongoing
2
164
Europe
JNJ-55308942, JNJ-55308942, Capsule
Janssen-Cilag International NV, Janssen Research & Development, LLC
Bipolar Depression Depresión Bipolar, Depression Depresión, Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
2021-003164-27: Evaluation of Safety, Pharmacodynamics and Pharmacokinetics of TW001 in Alzheimer Patients Evaluatie van veiligheid, farmacodynamiek en farmacokinetiek van TW001 in Alzheimer patiënten

Ongoing
2
150
Europe
TW001 granules for oral solution, TEST, Granules for oral solution
Treeway TW001AD B.V., Treeway TW001AD B.V.
Alzheimer´s Disease (AD) Ziekte van Alzheimer, Alzheimer's disease is a brain disorder that slowly destroys memory and thinking skills, and, eventually, the ability to carry out the simplest tasks. De ziekte van Alzheimer is een hersenaandoening die langzaam het geheugen en de denkvaardigheden vernietigt, en uiteindelijk het vermogen om de eenvoudigste taken uit te voeren., Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
2021-006861-39: A Phase 2 Clinical Trial of GH001 in Patients with Bipolar II Disorder and a Current Major Depressive Episode

Not yet recruiting
2
15
Europe
5-MeO-DMT 6,12 and 18mg powder in vial for reconstitution, GH001, Inhalation vapour, solution
GH Research Ireland Limited, GH Research Ireland Limited
Bipolar II Disorder, Form of mental illness where patients experience major depressive episodes and at least one hypomania episode., Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
CLIN-011, NCT04739423: A Study of CST-103 Co-administered With CST-107 in Subjects With Neurodegenerative Disorders

Active, not recruiting
2
41
Europe, RoW
CST-103, CST-107, matching placebo
CuraSen Therapeutics, Inc.
Mild Cognitive Impairment, Lewy Body Dementia, Parkinson's Disease Rapid Eye Movement Sleep Behavior Disorder, Parkinson's Disease Dementia
07/22
07/23
2021-006879-42: A phase 2 clinical trial of GH001 in patients with postpartum depression

Not yet recruiting
2
15
Europe
5-MeO-DMT 6, 12, 18mg, powder in vial for reconstitution, GH001, Inhalation vapour, solution
GH Research Ireland Limited, GH Research Ireland Limited
Post-Partum Depression, Depression associated with pregnancy and childbirth, Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
2021-005596-39: Long-term follow-up of safety and effectiveness of MDMA-assisted therapy for posttraumatic stress disorder Dlouhodobé sledování bezpečnosti a persistence MDMA-asistované terapie k léčbě posttraumatické stresové poruchy

Not yet recruiting
2
37
RoW
3,4- methylenedioxymethamphetamine hydrochloride, MDMA HCI, Capsule
MAPS Europe B.V., MAPS Europe B.V.
post-traumatic stress disorder (PTSD) Posttraumatická stresová porucha (PTSP), post-traumatic stress disorder, PTSD, Trauma Posttraumatická stresová porucha, PTSP, Trauma, Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
2021-006200-33: A Clinical Trial to Evaluate Efficacy and Safety of Psilocybin-Assisted Psychotherapy in Adults with Alcohol Use Disorder (AUD) Kliininen tutkimus, jossa arvioidaan psilosybiiniavusteisen psykoterapian tehokkuutta ja turvallisuutta aikuisilla, joilla on alkoholinkäytön häiriö (AUD)

Not yet recruiting
2
160
Europe
Psilocybin capsule 25 mg, Capsule
Clairvoyant Therapeutics Inc., Clairvoyant Therapeutics Inc.
Alcohol use disorder (AUD), Alcohol use disorder (AUD), Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
2022-000580-52: A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia

Not yet recruiting
2
600
Europe
Emraclidine, CVL-231, Tablet
Cerevel Therapeutics, LLC, Cerevel Therapeutics, LLC
Patients with schizophrenia who are experiencing an acute exacerbation of psychosis, Schizophrenia is mental disorder that exhibits problems with positive symptoms (e.g. hallucinations), negative symptoms (e.g. lack of motivation) and cognitive deficits (e.g. information processing)., Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
2020-005457-25: Study to assess the safety and efficacy of PCN-101 in treatment-resistant depression

Not yet recruiting
2
93
Europe
R-ketamine hydrochloride, PCN-101, Concentrate for solution for infusion
Perception Neuroscience, Inc, Perception Neuroscience, Perception Neuroscience, Inc.
Treatment-resistant depression, Treatment-resistant depression, Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
2022-000574-26: A randomized, double-blind, placebo-controlled, Phase 2b trial of GH001 in patients with treatment resistant depression

Not yet recruiting
2
80
Europe, RoW
GH001, GH001, Inhalation vapour, liquid
GH Research Ireland Limited, GH Research Ireland Ltd.
Treatment-resistant depression (TRD), Depression that has not improved with other treatments., Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
2021-006233-19: Efficacy and safety of COMP360 psilocybin therapy in anorexia nervosa: a proof-of-concept study

Not yet recruiting
2
60
Europe
COMP360, Capsule
COMPASS Pathfinder Limited, COMPASS Pathfinder Limited
Anorexia Nervosa (AN), Anorexia Nervosa (AN), Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
2021-003834-34: Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Subjects With Cognitive Impairment Associated With Schizophrenia Estudio para evaluar la eficacia, la seguridad y la tolerabilidad del Luvadaxistat en pacientes con deterioro cognitivo asociado a la esquizofrenia

Ongoing
2
308
Europe
Luvadaxistat, NBI-1065844, Tablet
Neurocrine Biosciences, Inc., Neurocrine Biosciences, Inc.
Cognitive Impairment Associated With Schizophrenia Deterioro cognitivo asociado a la esquizofrenia, Cognitive Impairment and Schizophrenia Deterioro Cognitivo y Esquizofrenia, Psychiatry and Psychology [F] - Behavioral Disciplines and Activities [F04]
 
 
2021-004927-34: Clinical study to investigate the efficacy, safety and tolerability of the test substance Ketamine hydrochloride prolonged release tablets compared to placebo in patients with treatment resistant depression.

Not yet recruiting
2
180
Europe, RoW
Ketamine Hydrochloride Prolonged Release Tablets, KET01, Prolonged-release tablet
Ketabon GmbH, Ketabon GmbH
Treatment-resistant depression, Treatment-resistant depression is defined as the intake of 2 different anti-depressant medications for a sufficient length of time at an adequate dose without an adequate improvement of the depression, Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
2022-003743-10: Study to Evaluate the Efficacy and Safety of Intranasal BPL-003 in Patients with Treatment Resistant Depression

Not yet recruiting
2
225
Europe
5-MeO-DMT.Benzoate Dry Powder, BPL-003, Nasal powder in single-dose container
Beckley Psytech Ltd., Beckley Psytech Ltd.
Treatment-Resistant Depression (TRD), Depression that has not improved with other treatments., Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
CANREST, NCT05253417: The CANabidiol Use for RElief of Short Term Insomnia

Completed
2
208
RoW
50 mg Cannabidiol (CBD), BodECS BioAbsorb(TM) capsule, Placebo, 100 mg Cannabidiol (CBD)
Bod Australia, Woolcock Institute of Medical Research
Sleep Disturbance, Insomnia, Insomnia Type; Sleep Disorder, Insomnia, Transient, Insomnia Due to Anxiety and Fear, Insomnia Due to Other Mental Disorder
07/23
07/23
2020-003720-16: Study of efficacy and safety of MIJ821 in addition to comprehensive standard of care on the rapid reduction of symptoms of Major Depressive Disorder in subjects who have suicidal ideation with intent

Not yet recruiting
2
195
Europe
MIJ821, MIJ821, Powder for solution for injection/infusion
Novartis Pharma AG, Novartis Pharma AG
Major Depressive Disorder with suicidal ideation with intent, Major Depression, Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
NCT05321498: Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation

Withdrawn
2
60
NA
XPro1595, INB03/XPro™, XENP1595, Dominant-negative Tumor Necrosis Factor (DN-TNF), Placebo, Matching Placebo
Inmune Bio, Inc.
Mild Cognitive Impairment (MCI), Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Mental Disorders
10/23
10/23
NCT05904717: Effect of PXS-4728A on Microglia Activation in Participants With Isolated Rapid Eye Movement Sleep Behaviour Disorder

Recruiting
2
40
Europe, RoW
PXS-4728 (A), Matching Placebo (B)
Pharmaxis
REM Sleep Behavior Disorder
09/24
01/25
MINDFuL, NCT05318976: A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation

Recruiting
2
201
Europe, Canada, RoW
XPro1595, INB03/XPro™, XENP1595, DN-TNF, Placebo, Matching Placebo
Inmune Bio, Inc.
Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders, Mild Cognitive Impairment
12/24
12/24
NCT05522387: An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease

Active, not recruiting
2
11
RoW
XPro1595, INB03/XPro™, XENP1595, DN-TNF
Inmune Bio, Inc.
Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
05/24
09/24
2018-004208-20: Phase 1/2 study of GH001 in depression

Not yet recruiting
1/2
16
Europe
GH001, Inhalation solution
Gh Research Limited, GH Research Limited
Treatment-resistant depression, Depression that has not responded sufficiently to previous treatment, Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
2012-000220-18: Effects of melatonin treatment, light therapy, and sleep improvement in children with sleep onset problems Onderzoek naar de effecten van melatonine, lichttherapie en slaapverbetering in kinderen met inslaapproblemen

Ongoing
1
192
Europe
Tablet, Bio-Melatonin
University of Amsterdam, University of Amsterdam, Pharma Nord
Delayed Sleep Phase Syndrome Verlaat slaapfase syndroom, Sleep onset problems Inslaapproblemen, Psychiatry and Psychology [F] - Behavioral Disciplines and Activities [F04]
 
 
2016-003529-41: What is the effect of cannabidiol on the function of microglia in patients with schizophrenia?

Not yet recruiting
1
36
Europe
Cannabidiol, Capsule, hard
University Medical Center Utrecht, Netherlands Organisation for Scientific Research
Schizophrenia patients, Schizophrenia patients, Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
2019-000989-38: A Study Investigate the Pharmacokinetics, Safety, and Tolerability of Balovaptan in Children Ages 2–4 Years with Autism Spectrum Disorder Un estudio uqe investiga la farmacocinética, la seguridad y la tolerabilidad del balovaptán en niños de 2 a 4 años con trastorno del espectro autista

Not yet recruiting
1
10
Europe
RO528-5119/F10, RO528-5119/F11, RO528-5119/F37, RO528-5119/F10, RO528-5119/F11, RO528-5119/F37, Dispersible tablet
Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd, F.Hoffman-La Roche Ltd.
Autism spectrum disorder (ASD) Trastorno del espectro autista (TEA), ASD is a neurodevelopmental disorder that impairs the ability to communicate and interact TEA es un trastorno del desarrollo neurológico que afecta la capacidad de comunicarse e interactuar, Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
2021-001337-40: STUDY TO DETERMINE EFFICACY AND SAFETY OF BXCL501 IN AGITATION ASSOCIATED WITH PEDIATRIC SCHIZOPHRENIA AND BIPOLAR DISORDER ESTUDIO PARA DETERMINAR LA EFICACIA Y LA SEGURIDAD DE BXCL501 EN LA AGITACIÓN ASOCIADA A ESQUIZOFRENIA Y TRASTORNO BIPOLAR PEDIÁTRICOS

Not yet recruiting
1
120
Europe
BXCL501, Buccal film
BioXcel Therapeutics, Inc., BioXcel Therapeutics, Inc.
Subject that meets DSM-5 criteria for schizophrenia, schizoaffective, or schizophreniform disorder, or other specified/unspecified schizophrenia spectrum and/or other psychotic disorders OR Subject meets DSM-5 criteria for bipolar disorder (bipolar I or II ). Pacientes que cumplan los criterios de DSM-5 para esquizofrenia, trastorno esquizoafectivo o trastorno esquizofreniforme u otro espectro de esquizofrenia especificado/no especificado uy otros trastornos psicóticos O Pacientes que cumplan los criterios de DSM-5 para trastorno bipolar (bipolar I o II)., Schizophrenia and bipolar disorder Esquizofrenia y trastorno bipolar, Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
NCT04922593: Relative Bioavailability of LY03010 Compared to Listed Drug

Completed
1
281
US
LY03010; paliperidone palmitate, INVEGA SUSTENNA
Luye Pharma Group Ltd.
Schizophrenia, Psychotic Disorders, Mood Disorders, Schizophrenia Spectrum, Mental Disorders, Antipsychotic Agents, Tranquilizing Agents, Central Nervous System Depressants, Physiological Effects of Drugs, Psychotropic Drugs, Neurotransmitter Agents, Molecular Mechanisms of Pharmacological Action
03/22
04/22
NCT05321602: Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder

Completed
1
89
US
LY03010 156 mg treatment group, deltoid, paliperidone palmitate, LY03010 156 mg treatment group, gluteal, LY03010 351 mg treatment group, deltoid, LY03010 351 mg treatment group, gluteal
Luye Pharma Group Ltd.
Schizophrenia, Psychotic Disorders, Mood Disorders, Schizophrenia Spectrum and Other Psychotic Disorders, Mental Disorders, Antipsychotic Agents, Tranquilizing Agents, Central Nervous System Depression, Physiological Effects of Drugs, Psychotropic Drugs, Neurotransmitter Agents, Molecular Mechanisms of Pharmacological Action
09/22
10/22
2022-002940-27: Stem cell treatment of autism spectrum disorders (ASD) and gastrointestinal problems in children. Stamcellebehandling af autismespektrumforstyrrelser (ASF) og mave-tarmproblemer hos børn.

Not yet recruiting
1
10
Europe
CSCC_ASC, CSCC_ASC5010, Concentrate and solvent for dispersion for injection
Cell2Cure ApS, Cell2Cure ApS
Children with autism spectrum disorder and gastrointestinal symptoms. Børn med autismespektrumforstyrrelser og mave-tarmproblemer., Children with autism spectrum disorder and gastrointestinal symptoms. Børn med autismespektrumforstyrrelser og mave-tarmproblemer., Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
RBD, NCT05922995: The Effects of Tasimelteon in Participants With REM Behavior Disorder

Not yet recruiting
1
20
US
Tasimelteon, Hetlioz
Brigham and Women's Hospital, Vanda Pharmaceuticals
REM Behavior Disorder
09/26
12/28
NRAMP, NCT00686946: The National Register of Antipsychotic Medication in Pregnancy

Recruiting
N/A
500
RoW
The Alfred, Janssen-Cilag Ltd., AstraZeneca, Hospira, now a wholly owned subsidiary of Pfizer
Pregnancy, Mental Disorders
12/25
12/25
NCT03497663: VIA Family - Family Based Early Intervention Versus Treatment as Usual

Completed
N/A
96
Europe
VIA Family intervention, Treatment As Usual, TAU
Mental Health Services in the Capital Region, Denmark, Municipality of Frederiksberg, Denmark, Ministry of the Interior and Health, Denmark, TrygFonden, Denmark
Early Intervention, Child of Impaired Parents, Child, Adolescent, Mental Disorders, Severe, Schizophrenia, Bipolar Disorder, Depressive Disorder, Recurrent, Psychotic Disorders, Parent-Child Relations
01/21
01/21
BioSanfilippo, NCT02298686: Biomarker for Sanfilippo Type A-B-C-D Disease

Withdrawn
N/A
1000
Europe, RoW
CENTOGENE GmbH Rostock
Mental Retardation, Developmental Delay
02/21
02/21
BioGM1BioGM2, NCT02298647: Biomarker for Gangliosidosis: BioGM1/BioGM2 (BioGM1/GM2)

Withdrawn
N/A
1000
Europe, RoW
CENTOGENE GmbH Rostock
Hepato-splenomegaly, Dysostosis Multiplex, Seizures, Mental Retardation
02/21
02/21
BioCDS, NCT02934854: Biomarker for Creatine Deficiency Syndromes

Withdrawn
N/A
1000
RoW
CENTOGENE GmbH Rostock
Intellectual Disability, Developmental Delay, Movement Disorder, Behavioral Disorder, Intractable Epilepsy
02/21
02/21
YOCO, NCT04413747: Yoga Pranayama Adjuvant to Treat Burden COVID-19

Not yet recruiting
N/A
1000
Europe
morning Yoga-based breathing support, First procedure, pre_lunch Yoga-based breathing support, Second procedure, pre_dinner Yoga-based breathing support, Third procedure
Health Ricerca e Sviluppo S.R.L., Swami Vivekananda Yoga Anusandhana Samsthana, Bangaluru , India, Yoga Experience Association,Cervia (Ra), Italy, EJTN GEIE, Brussellese, Belgium, Casa di Riposo e Ambulatorio Giardino St Lucia, Massa Lomabarda (Ra) Italy, Halnet Srl, Faenza (Ra), Italy
Coronavirus Infection, Cytokine Storm, Mental Disorder
06/21
09/21
NCT06165445: Optimizing tDCS Protocol for Clinical Use in Major Depressive Disorder

Completed
N/A
60
RoW
transcranial direct current stimulation (tDCS), multichannel transcranial direct current stimulation (tDCS)
The National Brain Mapping Laboratory (NBML), Leibniz-Institut für Arbeitsforschung, Neuroelectrics Corporation, Zanjan University of Medical Sciences
Depressive Disorder, Cognitive Impairment, Psychiatric Disorder
12/22
03/23
NCT05068089: Health, Economic Analysis and Clinical Aspects of Patients With Neurological Disabilities in Enteral Nutrition With Dedicated Formula. The Role of Nissen's Fundoplication in the Management of Gastroesophageal Reflux

Not yet recruiting
N/A
360
Europe
Nissen fundoplication, Enteral nutrition
Bambino Gesù Hospital and Research Institute, Nestlé Health Science Spain
Gastro-Esophageal Reflux, Fundoplication
02/22
04/22
VIA Family, NCT06218693: 4 Year Follow-up of a Family-based Preventive Intervention

Completed
N/A
113
Europe
VIA Family, Treatment As Usual (TAU)
Mental Health Services in the Capital Region, Denmark, TrygFonden, Denmark, Child and Adolescent Mental Health Services, Research Unit, Capital Region, Denmark
Mental Disorder
01/24
01/24
RHAPSODY, NCT04939818: Clinical Feasibility of Speech Phenotyping for Remote Assessment of Neurodegenerative and Psychiatric Disorders

Completed
N/A
172
Europe
Novoic Limited, King's College London
Alzheimer Disease, Mild Cognitive Impairment, Dementia With Lewy Bodies, Dementia, Vascular, Frontotemporal Dementia, Primary Progressive Aphasia, Parkinson Disease, Motor Neuron Disease, Major Depressive Disorder, Bipolar Disorder, Amyotrophic Lateral Sclerosis
09/22
09/22
AP4ID, NCT03998605: Protect Yourself: Abuse Prevention for People With Intellectual Disabilities

Withdrawn
N/A
100
US
Abuse Prevention Program, Control Condition
Double S Instructonal Systems, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Abuse Prevention
11/22
12/22
NCT05336487: Physical Activity, Sports and Health in Adults With Intellectual Disabilities

Active, not recruiting
N/A
85
Europe
Physical activity
University of Copenhagen, Novo Nordisk A/S, Elsass Foundation
Intellectual Disability
12/22
12/22
NCT05731102: Diagnostic Survey of Mental and Substance Use Disorders Among Norwegian College and University Students

Completed
N/A
9585
Europe
Electronic version of the Composite International Diagnostic Interview 5th version (E-CIDI 5.0)
Norwegian Institute of Public Health, Statistics Norway, Society of Interventional Oncology
Mental Disorders, Substance Use Disorders, Treatment, Participation
02/23
02/23
NCT05206734: Risk of Mental Health Conditions in Children and Young Adults With Inflammatory Bowel Disease and Influence on Health

Completed
N/A
19469
Europe
Exposure of mental health condition
Momentum Data, Optimum Patient Care
Inflammatory Bowel Diseases, Depressive Episode, Recurrent Depressive Disorder, Anxiety Disorder, Psychological Disorder, Self Harm, Suicide, Attempted, Parasuicide, Eating Disorders, Body Image Disorder, Attention Deficit Hyperactivity Disorder, Behavioral Disorder, Adjustment Disorders, Acute Stress Disorder, Schizophrenia, Bipolar Disorder, Post-traumatic Stress Disorder, Sleep Disturbance
03/23
08/23
HEPASAME21, NCT04891445: Hepatitis C in Severe Mental Disorders: Nursing Programme

Recruiting
N/A
276
Europe
Nursing monitoring program, Clinical Path, As usual
Hospital Regional de Malaga, University of Malaga, Gilead Sciences, Instituto de Investigación Biomédica de Málaga (IBIMA).
Hepatitis C, Severe Mental Disorder
05/23
12/23
NCT06372210: A Trial to Assess a Wearable Patch's Functioning to Detect Medication Ingestion

Completed
N/A
54
US
Placebo IEM tablet, Abilify MyCite®, OPC-14597 Digital, D-Tect Patch
Otsuka Pharmaceutical Development & Commercialization, Inc.
Mental Disorder, Schizophrenia, Major Depressive Disorder, Bipolar I Disorder
07/23
07/23
NCT05394779: DEMETRA - ADVICE-002-2022

Active, not recruiting
N/A
246
Europe
DTXO APP, PLACEBO APP - Control group
Advice Pharma Group srl
Obesity, Health Behavior, Life Style, Dietary Habits, Weight Loss, Diet, Healthy, Diet Habit, Body Weight, Nutrition Disorders, Nutrition, Healthy, Overweight and Obesity, Behavioral Disorder
06/24
06/24
NCT05940168: Internet-delivered ACT (I-Navigator ACT) for Parents of Children With Disabilities

Active, not recruiting
N/A
134
Europe
I-Navigator ACT, Navigator ACT group
Karolinska Institutet, Region Stockholm, Forte, Stiftelsen Frimurarna Barnhuset
Parents, Stress, Psychological, Anxiety, Depression, Neurodevelopmental Disorders, Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder, Intellectual Disability, Physical Disability, Traumatic Brain Injury
11/23
11/23
NCT04851912: Speech-based Digital Biomarker for Psychiatric Disease

Active, not recruiting
N/A
200
Canada
Winterlight Apps
Winterlight Labs
Speech, Psychiatric Disorder, Language
12/23
12/23
INT_REF_MH, NCT04832035: Integration of Refugees Into Public Mental Health Care

Recruiting
N/A
120
Europe
"coordinated and peer supported mental health care", "standard psychotherapeutic care in the public healthcare system"
University of Konstanz, Vivo international e.V.
Psychiatric Disorders From Chapters 3 and 4 of ICD10
12/23
06/24
Slow-SPEED-NL, NCT06193252: Slowing Parkinson's Early Through Exercise Dosage-Netherlands

Recruiting
N/A
110
Europe
Increase of physical activity volume and intensity with the use of a motivational smartphone application
Radboud University Medical Center, Stichting ParkinsonNL, ZonMw: The Netherlands Organisation for Health Research and Development, Michael J. Fox Foundation for Parkinson's Research, PARKINSONS UK, Cure Parkinsons, Edmond J. Safra Foundation, Davis Phinney Foundation, Donders Centre for Cognitive Neuroimaging, Radboud University Nijmegen, Anne Wojcicki Foundation, Sleep Medicine Centre Kempenhaeghe, Sleep Medicine Centre SEIN, Queen Mary University of London, 23andMe, Inc., Parkinsons Progression Markers Initiative (PPMI), Massachusetts General Hospital, Harvard School of Public Health (HSPH), IJsfontein B.V., Netherlands, Hoffmann-La Roche, Erasmus Medical Center, University of Illinois at Chicago, University of Rochester, University of Bristol, University of Plymouth, University of Luebeck, McGill University, University of Pittsburgh
Parkinson Disease, Prodromal Stage, Neurodegenerative Diseases, Parkinsonian Disorders, REM Sleep Behavior Disorder, Basal Ganglia Diseases, Central Nervous System Diseases, Synucleinopathies, Nervous System Diseases, Cerebral Disorder, Brain Diseases
12/26
12/26
PRIME, NCT04975750: A Problem Solving Intervention Involving Employees at Risk of Sick Leave Due to Common Mental Disorders

Active, not recruiting
N/A
170
Europe
Problem solving intervention, Care as usual
Karolinska Institutet, AFA Insurance
Mental Disorders
12/24
12/24
NCT06312410: The VIA Family 2.0 - a Family Based Intervention for Families With Parental Mental Illness

Not yet recruiting
N/A
1452
NA
VIA Family 2.0
Mental Health Services in the Capital Region, Denmark, Aalborg Psychiatric Hospital, TrygFonden, Denmark, Novo Nordisk A/S, Lundbeck Foundation, Liljeborgfonden, Ebbefos Fonden, KV Fonden
Child, Parents, Mental Disorder, Child of Impaired Parents, Preventive Health Services
12/27
12/28
NCT05295277: Validation of Optical Genome Mapping for the Identification of Constitutional Genomic Variants in a Postnatal Cohort

Recruiting
N/A
1000
US
Standard of care genetic testing group
Bionano Genomics, University of Rochester, Columbia University, Greenwood Genetic Center, Praxis Genomics, Augusta University, Medical College of Wisconsin, University of Iowa
Developmental Disability, Intellectual Disability, Autism Spectrum Disorder, Congenital Anomaly, Fragile X Syndrome, Facioscapulohumeral Muscular Dystrophy 1
03/24
06/24
THRIVE, NCT06425523: Transforming Health and Resilience In Vulnerable Environments: Mental Health, Psychosocial Support, and Climate-Smart Farming in Nakivale

Not yet recruiting
N/A
900
NA
Home Gardening Intervention (HGI), Self-Help Plus (SH+), Enhanced Usual Care (EUC)
Uppsala University, The Swedish Research Council for Environment, Agricultural Sciences and Spatial Planning (FORMAS), Vivo international e.V., Bielefeld University, Kabale University, University of Turku, Max Planck Institute for Research on Collective Goods, University of North Carolina at Charlotte
Psychological Distress, Malnutrition, Child, Dietary Deficiency, Mental Health, Malnutrition
09/25
12/26
NCT04909203: iKinnect2.0 for Juvenile Justice Involved Youth at Risk for Suicide

Not yet recruiting
N/A
240
US
iKinnect2.0, Active Control App
Evidence-Based Practice Institute, Seattle, WA, National Institute of Mental Health (NIMH), University of Maryland
Child Behavior Disorders, Suicide and Self-harm
07/24
07/24
NCT05933005: Intervention Utilizing a Computerized Cognitive Rehabilitation Program (D-kit/EF1)

Recruiting
N/A
80
US
D-kit/EF1, Sham group program
University of California, San Francisco, DoBrain Inc.
Mild Intellectual Disability, Borderline Intellectual Functioning
08/24
10/24
LANDSCAPE, NCT04943796: A Study to Learn About the Occurrence of ADHD in Adults With Mental Conditions and Their Quality of Life

Recruiting
N/A
576
Europe, Canada
Takeda
Attention Deficit Hyperactivity Disorder (ADHD)
09/24
09/24
ACIST, NCT03724136: Alzheimer's Autism and Cognitive Impairment Stem Cell Treatment Study

Enrolling by invitation
N/A
100
US, RoW
Intravenous Bone Marrow Stem Cell (BMSC) Fraction, Intranasal Topical Bone Marrow Stem Cell (BMSC) Fraction, Near Infrared Light
MD Stem Cells
Alzheimer Disease, Alzheimer Dementia, Vascular Dementia, Lewy Body Disease, Lewy Body Dementia With Behavioral Disturbance (Disorder), Dementia, Mixed, Parkinson-Dementia Syndrome, Chronic Traumatic Encephalopathy, Huntington's Dementia, Wernicke Korsakoff Syndrome, Traumatic Brain Injury, Dementia, Multi-Infarct, Autism, Autism Spectrum Disorder, Autistic Behavior, Autistic Disorder, Current or Active State, Cadasil, LATE Limbic-predominant Age-related TDP-43 Encephalopathy
07/25
07/25
NCT05615324: SAFIR Family Talk - Investigating the Effect of The Family Talk Intervention

Recruiting
N/A
800
Europe
Family Talk Preventive Intervention, Beardslee's Family Intervention
Mental Health Services in the Capital Region, Denmark, TrygFonden, Denmark, Sektion for Tværsektoriel forskning - Region Hovedstaden
Mental Disorder, Family, Child, Parenting, Resilience, Prevention
12/24
10/25
NCT05749419: Vaccinations and People With Disabilities

Recruiting
N/A
1000
RoW
Hadassah Medical Organization, Merck Sharp & Dohme LLC
Vaccine Refusal, Compliance, Patient, Disability, Intellectual, Congenital Disorders, Pediatric Disorder
01/25
01/26
DRRRP-PHN, NCT05018351: Peer Navigators for the Health and Wellness of People With Psychiatric Disabilities

Recruiting
N/A
354
US
Integrated Care, Peer Navigation
Illinois Institute of Technology, Arizona State University, Thresholds Inc.
Mental Disorder, Physical Illness
09/25
09/25
NCT03047369: The Myelin Disorders Biorepository Project

Recruiting
N/A
12000
US
Children's Hospital of Philadelphia, National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), National Center for Advancing Translational Sciences (NCATS), Affinia Therapeutics, Biogen, Eli Lilly and Company, Homology Medicines, Inc, Myrtelle Inc., Orchard Therapeutics Ltd., Passage Bio, Inc., Synaptix Biotherapeutics Ltd., Takeda, Boehringer Ingelheim, Ionis Pharmaceuticals, Sanofi Winthrop Industrie, Sana Biotechnology, Inc., Yaya Foundation for 4H Leukodystrophy, University of Pennsylvania
Leukodystrophy, White Matter Disease, Leukoencephalopathies, 4H Syndrome, Adrenoleukodystrophy, AMN, ALD, ALD Gene Mutation, ALD (Adrenoleukodystrophy), X-linked Adrenoleukodystrophy, X-ALD, Adrenomyeloneuropathy, Aicardi Goutieres Syndrome, AGS, Alexander Disease, Alexanders Leukodystrophy, AxD, ADLD, Canavan Disease, CTX, Cerebrotendinous Xanthomatoses, Krabbe Disease, GALC Deficiency, Globoid Leukodystrophy, TUBB4A-Related Leukodystrophy, H-ABC - Hypomyelination, Atrophy of Basal Ganglia and Cerebellum, HBSL, HBSL - Hypomyelination, Brain Stem, Spinal Cord, Leg Spasticity, LBSL, Leukoencephalopathy With Brain Stem and Spinal Cord Involvement and High Lactate Syndrome (Disorder), Leukoencephalopathy With Brainstem and Spinal Cord Involvement and Lactate Elevation, ALSP, CSF1R Gene Mutation, HCC - Hypomyelination and Congenital Cataract, MLC1, Megalencephalic Leukoencephalopathy With Subcortical Cysts, MLD, Metachromatic Leukodystrophy, PMD, Pelizaeus-Merzbacher Disease, PLP1 Null Syndrome, PLP1 Gene Duplication | Blood or Tissue | Mutations, Pelizaeus Merzbacher Like Disease, Peroxisomal Biogenesis Disorder, Zellweger Syndrome, Refsum Disease, Salla Disease, Sialic Storage Disease, Sjögren, Sjogren-Larsson Syndrome, Van Der Knapp Disease, Vanishing White Matter Disease, Charcot-Marie-Tooth, CMT, Mct8 (Slc16A2)-Specific Thyroid Hormone Cell Transporter Deficiency, Allan-Herndon-Dudley Syndrome, Cadasil, Cockayne Syndrome, Multiple Sulfatase Deficiency, Gangliosidoses, GM2 Gangliosidosis, BPAN, Labrune Syndrome, LCC, Mucopolysaccharidoses, TBCK-Related Intellectual Disability Syndrome
12/30
12/30
 

Download Options